Dyslipidemia, occurring along with the progression of CKD, is characterized by (1) hypertriglyceridemia, (2) decrease in HDL-C and apolipoprotein (apo) AI (apoA-I), (3) increase in IDL-C and chylomicron remnants, followed by (4) reduced apoC-II/apoC-III ratio. This evidence concerns the gene APOA1 and chronic kidney disease.